WBRT alone

Related by string. * : radiation therapy WBRT . WBRT . WBRT plus / alones . ALONE . Alone : Shell Stand Alone . Never Walk Alone . nucleoside analogues alone . Alone AR . Walk Alone . George Gershwin Alone . alone . Sleep Alone . Eat Alone . ATAC Arimidex Tamoxifen Alone . Stand Alone . Painfully Alone . Stands Alone . Arimidex Tamoxifen Alone . Alone doji . Die Alone . Dine Alone Records * *

Related by context. Frequent words. (Click for all words.) 64 plus prednisone 62 plus dexamethasone 62 mg QD 61 docetaxel chemotherapy 61 carboplatin paclitaxel 61 relapsed refractory multiple myeloma 60 plus gemcitabine 59 chlorambucil 58 R sorafenib tablets 58 relapsed multiple myeloma 58 dacarbazine 57 FOLFIRI 57 irbesartan 57 primary hypercholesterolemia 56 free survival PFS 56 Pegasys ® 56 dose cohorts 56 metastatic hormone refractory 56 mg BID 56 multicenter Phase 56 Secondary endpoints included 56 mg kg dose 56 clopidogrel Plavix 56 active comparator 55 KRAS wild 55 Median survival 55 paclitaxel chemotherapy 55 peginterferon alfa 2b 54 discontinuations due 54 Secondary endpoints include 54 nab paclitaxel 54 cytogenetic response 54 Secondary endpoints 54 Amrubicin 54 patients evaluable 54 median PFS 54 heavily pretreated 54 PREZISTA r 54 Expanded Disability Status 53 pertuzumab 53 peginterferon alfa 2a 53 IMC A# 53 % CI #.#-#.# [007] 53 elotuzumab 53 P = .# 52 axitinib 52 low dose dexamethasone 52 events SAEs 52 % CI #.#-#.# [003] 52 phase IIb clinical 51 Imprime PGG 51 annualized relapse 51 placebo controlled Phase 51 placebo controlled clinical 51 patients undergoing percutaneous 51 bosentan 51 diabetic neuropathic pain 50 LVEF 50 pharmacodynamics 50 dose escalation trial 50 HGS ETR1 50 pg mL 50 acute coronary syndromes ACS 50 GRN#L 50 Phase 2b clinical 50 Phase 1b trial 50 liposomal formulation 50 RECIST criteria 50 placebo controlled clinical trials 49 tolvaptan 49 double blinded placebo 49 ng dL 49 multi kinase inhibitor 49 Pivotal Phase 49 ascending doses 49 Phase 2a clinical 49 lixisenatide 49 safety tolerability pharmacokinetics 49 ISENTRESS 48 Phase Ib clinical 48 BAY #-# 48 PEG SN# 48 dose regimens 48 % CI #.#-#.# [006] 48 μg L 48 Response Evaluation Criteria 48 randomized #:# 48 label dose escalation 48 Pivotal Trial 48 SCH # 48 ponatinib 48 Azedra 48 biochemical recurrence 48 Phase III randomized 48 pg ml 47 blinded placebo controlled 47 pharmacokinetics PK 47 Pegasys R 47 dose escalation 47 Phase 2b study 47 #mg dose [001]

Back to home page